Company: HURA
Filing Date: 2025-05-06
Form Type: CORRESP
Source: 0001193125-25-113948
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: CORRESP
Chunk 0
---
| 100 N TAMPA ST                    
 SUITE 2700                        
 TAMPA, FL 33602-5810              
 813.229.2300 TEL 813.221.4210 FAX 
 FOLEY.COM                         |

May 6, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549

| Attention: | Jessica Dickerson |

| Joe McCann |

| Re: | TuHURA Biosciences, Inc. |

| Registration Statement on Form S-4 |

| File No. 333-284787 |

Ladies and Gentlemen: This letter is submitted on behalf of TuHURA Biosciences, Inc. (the “ Company” or “ TuHURA”) in response to the comments of the staff of the Division of Corporation Finance (the “ Staff”) of the U.S. Securities and Exchange Commission (the “ Commission”) with respect to the Company’s Registration Statement on Form S-4(File No: 333-284787),initially filed on February 7, 2025 (the “ Registration Statement”), as set forth in the Staff’s letter dated February 20, 2025 (the “ Comment Letter”). The Company is concurrently submitting Amendment No. 1 to the Registration Statement (“ Amendment No. 1”), which includes changes to reflect responses to the Staff’s comments and other updates. For reference purposes, the text of the Comment Letter has been reproduced herein with our response below the comment. For your convenience, we have italicized the reproduced Staff comment from the Comment Letter. Unless otherwise indicated, page references in the descriptions of the Staff’s comment refer to the Registration Statement, and page references in the response refer to Amendment No. 1. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Amendment No. 1. Registration Statement on Form S-4 General

| 1. | We note that your proxy statement/prospectus includes your annual and interim financial                                                                                                                                                       
 statements, as well as annual and interim financial statements for Kintara Therapeutics, Inc. and Kineta, Inc. However, we note that the proxy statement/prospectus only includes a management’s discussion                                   
 and analysis for the periods covered by your interim financial statements and Kineta’s interim financial statements. Please revise your proxy statement/prospectus to include a management’s discussion and analysis covering all the periods 
 covered by the financial statements